$1.87
6.03% day before yesterday
Nasdaq, Jan 02, 10:15 pm CET
ISIN
US05280R1005
Symbol
AUTL

Autolus Therapeutics plc Stock price

$1.87
+0.53 39.55% 1M
-0.48 20.43% 6M
-0.12 6.03% YTD
-0.76 28.90% 1Y
-0.03 1.58% 3Y
-7.49 80.02% 5Y
-23.13 92.52% 10Y
-23.13 92.52% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.12 6.03%
ISIN
US05280R1005
Symbol
AUTL
Industry

Key metrics

Basic
Market capitalization
$529.6m
Enterprise Value
$421.6m
Net debt
positive
Cash
$367.4m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.4 | 6.8
EV/Sales
8.2 | 5.4
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
54.6%
Return on Equity
-51.6%
ROCE
-47.3%
ROIC
-101.4%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$51.1m | $77.9m
EBITDA
$-264.7m | $-266.6m
EBIT
$-273.9m | $-269.7m
Net Income
$-224.8m | -
Free Cash Flow
$-306.1m
Growth (TTM | estimate)
Revenue
406.7% | 669.5%
EBITDA
-89.2% | -14.4%
EBIT
-86.0% | -12.0%
Net Income
-6.1% | -
Free Cash Flow
-48.9%
Margin (TTM | estimate)
Gross
-61.2%
EBITDA
-517.7% | -342.3%
EBIT
-535.8%
Net
-439.7% | -
Free Cash Flow
-598.6%
More
EPS
$-0.8
FCF per Share
-
Short interest
6.0%
Employees
649
Rev per Employee
$20.0k
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
94%
Hold
6%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
51 51
407% 407%
100%
- Direct Costs 82 82
-
161%
-31 -31
-
-61%
- Selling and Administrative Expenses 130 130
112% 112%
254%
- Research and Development Expense 113 113
17% 17%
221%
-265 -265
89% 89%
-518%
- Depreciation and Amortization 9.26 9.26
25% 25%
18%
EBIT (Operating Income) EBIT -274 -274
86% 86%
-536%
Net Profit -225 -225
6% 6%
-440%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Neutral
GlobeNewsWire
26 days ago
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.
Neutral
GlobeNewsWire
26 days ago
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel's adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T persist...
Neutral
GlobeNewsWire
about one month ago
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company's Board of Directors.
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 649
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today